<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343551</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2351</org_study_id>
    <nct_id>NCT00343551</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.</brief_title>
  <official_title>A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and&#xD;
      safety of aliskiren given to hypertensive patients after a missed dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour ambulatory diastolic blood pressure (MADBP) change from baseline, after a missed dose, aliskiren 300 mg versus irbesartan 300mg.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>from baseline.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean 24-hour ambulatory diastolic blood pressure (MADBP) change from baseline, after a missed dose, ramipril 10 mg versus irbesartan 300mg.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy on mean 24 hour ambulatory systolic blood pressure (MASBP) change</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>from baseline following a missed dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy on daytime and nighttime MASBP and MADBP change from baseline following a missed dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy on the MASBP and MADBP change from baseline following the last active dose prior to introducing a missed dose in any treatment group.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy on the daytime and nighttime MASBP and MADBP change from baseline, following the last active dose prior to introducing a missed dose in any treatment group.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
  </secondary_outcome>
  <enrollment>654</enrollment>
  <condition>Essential Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients 18 years of age and older.&#xD;
&#xD;
          -  Patients must meet following blood pressure criteria:&#xD;
&#xD;
        At Visit 2 : Office Mean Sitting Diastolic Blood Pressure ≥ 90 mmHg and &lt; 110 mmHg At Visit&#xD;
        3 : Office Mean Sitting Diastolic Blood Pressure ≥ 95 mmHg and &lt; 110 mmHg before&#xD;
        application of Ambulatory Blood Pressure Measurement device At Visit 3 : 24-hr Mean&#xD;
        Ambulatory Diastolic Blood Pressure ≥ 85 mmHg&#xD;
&#xD;
          -  Patient must have an absolute difference of ≤ 10 mmHg in their office Mean Sitting&#xD;
             Diastolic Blood Pressure between Visit 2 and 3.&#xD;
&#xD;
          -  Male or female patients are eligible. Female patients must be either post-menopausal&#xD;
             for at least one year, surgically sterile or using effective contraceptive methods&#xD;
             such as oral contraceptives, barrier method with spermicide or an intrauterine device.&#xD;
             Reliable contraception should be maintained throughout the study and for 7 days after&#xD;
             study drug discontinuation.&#xD;
&#xD;
          -  Patients who are eligible and able to participate in the study, and who consent to do&#xD;
             so after the purpose and nature of the investigation has been clearly explained to&#xD;
             them (written informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hypertension [Office Mean Sitting Diastolic Blood Pressure ≥ 110 mmHg and/or&#xD;
             office mean sitting systolic blood pressure (MSSBP) ≥ 180 mmHg].&#xD;
&#xD;
          -  Current diagnosis of heart failure (NYHA Class II-IV).&#xD;
&#xD;
          -  History of myocardial infarction, coronary bypass surgery, or any percutaneous&#xD;
             coronary intervention (PCI) during the 12 months prior to Visit 1.&#xD;
&#xD;
          -  Known or suspected contraindications to the study medications, including history of&#xD;
             allergy to ACE-Inhibitors or ARBs.&#xD;
&#xD;
          -  Upper arm circumference &gt; 42 cm.&#xD;
&#xD;
          -  Third shift or night workers.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. 2010 Feb;24(2):93-103. doi: 10.1038/jhh.2009.38. Epub 2009 May 21.</citation>
    <PMID>19458624</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <keyword>Hypertension, ambulatory blood pressure, missed dose, aliskiren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

